0000000000618719

AUTHOR

A. Mammarella

showing 2 related works from this author

Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia.

2007

In order to assess the long-term (12 months) efficacy and safety of fenofibrate administered with simvastatin in the treatment of primary mixed hyperlipidaemia, we conducted a study that compared increasing dosages of these drugs in subgroups of men and women belonging to a clinical sample of outpatients. This was an open study carried out in patients with primary mixed hyperlipidaemia (lipoprotein phenotype IIb) who needed a combined therapeutic approach because of their poor response to a single-drug regimen with an HMG-CoA reductase inhibitor (simvastatin). Thus, a fibrate (fenofibrate) was added to the therapy. The study lasted 12 months. Forty-five patients (mean age: 58.9 ± 11.3 years…

medicine.medical_specialtyFenofibrateDosemedicine.drug_classbusiness.industrynutritional and metabolic diseasesGeneral MedicineFibratePharmacologyGastroenterologyDiscontinuationRegimenTolerabilitySimvastatinInternal medicinemedicinelipids (amino acids peptides and proteins)Pharmacology (medical)Adverse effectbusinessmedicine.drugClinical drug investigation
researchProduct

Prophylaxis of venous thromboembolism in elderly patients with multimorbidity

2013

none 327 si Pharmacological thromboprophylaxis (TP) is known to reduce venous thromboembolism (VTE) in medical inpatients, but the criteria for risk-driven prescription, safety and impact on mortality are still debated. We analyze data on elderly patients with multimorbidities admitted in the year 2010 to the Italian internal medicine wards participating in the REPOSI registry to investigate the rate of TP during the hospital stay, and analyze the factors that are related to its prescription. Multivariate logistic regression, area under the ROC curve and CART analysis were performed to look for independent predictors of TP prescription. Association between TP and VTE, bleeding and death in …

MaleTVPSettore MED/09 - Medicina InternaComorbidityLogistic regressionFondaparinuxVENOUS THROMBOEMBOLISM; THROMBOPROPHYLAXIS; Medical PatientsMedical patients; Thromboprophylaxis; Venous thromboembolism; Aged; Aged 80 and over; Area Under Curve; Comorbidity; Female; Hospital Mortality; Hospitalization; Humans; Logistic Models; Male; Propensity Score; Venous Thromboembolism; Internal Medicine; Emergency MedicineThromboprophylaxis Venous thromboembolism Medical patients80 and overHospital MortalityAged 80 and overSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheMedical patients; Thromboprophylaxis; Venous thromboembolism; Aged; Aged; 80 and over; Area Under Curve; Comorbidity; Female; Hospital Mortality; Hospitalization; Humans; Logistic Models; Male; Propensity Score; Venous Thromboembolism; Internal Medicine; Emergency Medicineprophylaxis; venous thromboembolism; elderlyHospitalizationArea Under CurveEmergency MedicineFemaleprophylaxismedicine.drugVenous thromboembolismmedicine.medical_specialtyThromboprophylaxis; Venous thromboembolismmultimorbidityBarthel indexvenous thromboembolismMEDLINEMedical patients; Thromboprophylaxis; Venous thromboembolism; Aged; Aged 80 and over; Area Under Curve; Comorbidity; Female; Hospital Mortality; Hospitalization; Humans; Logistic Models; Male; Propensity Score; Venous Thromboembolism; Emergency Medicine; Internal Medicineelderly patientselderlyMedical patientsInternal medicineInternal MedicinemedicineHumansMedical prescriptionprophylaxis; venous thromboembolism; elderly patientsPropensity ScoreIntensive care medicineThromboprophylaxisAgedbusiness.industryprophylaxiMedical patients; Thromboprophylaxis; Venous thromboembolismprophylaxis; Venous thromboembolism; Elderly; multimorbidity; medical patients; thromboprophylaxismedicine.diseaseComorbidityLogistic ModelsPropensity score matchingbusinessVenous thromboembolism
researchProduct